Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma - Top-Institutions - MDSpire

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

  • By

  • Joseph B. Parker

  • Richard W. Joseph

  • Vera J. Suman

  • Yiyi Yan

  • Ruqin Chen

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Los Angeles
    University of California, Los Angeles

    Los Angeles, CA

    Key Differentiators

    • Dermatology
    • Oncology

  • #2

    Gustave Roussy Cancer Campus
    Gustave Roussy Cancer Campus

    Villejuif, Île-de-France

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Dermatology

  • #4

    University of Pittsburgh School of Medicine
    University of Pittsburgh School of Medicine

    Pittsburgh, PA

    Key Differentiators

    • Oncology
    • Dermatology

  • #5

    Perlmutter Cancer Center
    Perlmutter Cancer Center

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma

  • by Joseph B. Parker, Richard W. Joseph, Vera J. Suman, Yiyi Yan, Ruqin Chen

  • June 10, 2026

Related Content

Editorial: New Insights on Sialic Acid and Sialylated Glycans in the Tumorigenic Process

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

Clinical utility of an optoelectronic imaging tracing system for diagnosis of high-grade cervical lesions